Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.  In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.  Studies establishing effectiveness included predominantly patients with WHO Functional Class II-III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).  For more information call 1-888-417-3172 or go to www.ambrisentanrems.us.com.

Ambrisentan Tablets
  • Compare to
    Letairis®*
*Letairis® is a registered trademark of Gilead Sciences, Inc.

Ambrisentan Tablets (5 mg)

  • Package size
    30 ct
  • Rating
    AB
  • Strength
    5 mg
  • NDC Code
    42794-0051-08
Ambrisentan Tablets (5 mg)

Ambrisentan Tablets (10 mg)

  • Package size
    30 ct
  • Rating
    AB
  • Strength
    10 mg
  • NDC Code
    42794-0052-08
Ambrisentan Tablets (10 mg)

 

* Disclaimer: All images shown are for illustrative purposes only. Actual product may vary due to image enhancement. The images and information for a particular product may change over time. For the most up-to-date product information, please contact Sigmapharm Laboratories, LLC.